TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03872830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours.
Study: NCT02730546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT03124914

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular tests
Description: Neuromuscular tests
Study: NCT02730546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo curative-intent surgery
Study: NCT01644812

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching
Study: NCT01573611

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape Powder
Description: 36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
Study: NCT02630355

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Remote Ischaemic Preconditioning
Description: Inflation of blood pressure cuff in lower limb

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischaemic Preconditioning
Description: Inflation of blood pressure cuff in lower limb
Study: NCT04056715

Intervention type: DEVICE
Intervention: Zio XT
Description: ambulatory cardiac monitoring device
Study: NCT01406366

Intervention type: BEHAVIORAL
Intervention: Group 1: Bright Futures Oral Health Curriculum
Description: Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.

Intervention type: BEHAVIORAL
Intervention: Group 2: Iron Deficiency Training Module
Description: Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
Study: NCT03011424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal liver support therapy (ELS)
Description: ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
Study: NCT01842334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT administered to to both DCS and placebo group.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: CBT administered to to both DCS and placebo group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: NRT administered to both DCS and placebo group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: NRT administered to both DCS and placebo group.
Study: NCT04139603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic kinesio taping
Description: Kinesio tapes applied to the lumbopelvic region will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal supported lumbopelvic kinesio taping
Description: Kinesio tapes applied to the lumbopelvic region and abdominal area will stay 3 days. They will be removed from the sites, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tapng
Description: Placebo tapes (just like Kinesio tapes) applied to the lumbopelvic region without any tension will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided.
Study: NCT02615561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)
Description: 2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New cosmetic Bepanthen product: Pumpkin (BAY207543)
Description: Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stelatopia (cosmetic comparator)
Description: Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
Study: NCT02268942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartWare HVAD
Description: Implant of HeartWare HVAD via thoracotomy implant technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Description: Thoracotomy implant technique
Study: NCT02169466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® HBS
Description: controlled-release levodopa 100 mg/benserazide 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® HBS
Description: controlled-release levodopa 100 mg/benserazide 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® HBS
Description: controlled-release levodopa 100 mg/benserazide 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® HBS
Description: controlled-release levodopa 100 mg/benserazide 25 mg
Study: NCT02630355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischaemic Preconditioning
Description: Inflation of blood pressure cuff in lower limb

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischaemic Preconditioning
Description: Inflation of blood pressure cuff in lower limb
Study: NCT00296478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endometrin
Description: Endometrin 100mg BID x 10weeks
Study: NCT03461705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volcano Verrata Pressure Wire
Description: Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: St. Jude Medical (SJM) Aeris Pressure Wire System
Description: The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.
Study: NCT04321590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)
Description: Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)
Description: Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)
Description: Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)
Description: Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
Study: NCT00994890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Description: Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Description: Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg
Description: Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
Study: NCT03323385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: Once Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once Daily
Study: NCT00890201

Intervention type: PROCEDURE
Intervention: Gallbladder bile sampling and intraoperative cholangiography
Description: Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished

Intervention type: PROCEDURE
Intervention: Gallbladder bile sampling and intraoperative cholangiography
Description: Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished
Study: NCT01087229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: equimolar oxygen-nitrous oxide mixture
Description: Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Kinesitherapy is performed with a mask by which patient inhales a placebo.
Study: NCT02347202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online counseling via Zoom teleconferencing

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone support as needed
Study: NCT02928029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Sequential dose escalation in Intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Sequential dose escalation in Intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Sequential dose escalation in Intravenous (IV) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is administered orally at 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is administered orally at 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is administered orally at 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is administered orally at 40 mg
Study: NCT01118884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
Study: NCT04690556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis (ranibizumab)
Description: Lucentis® 0.5 mg via intravitreal injection once monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUBT010 (proposed ranibizumab biosimilar)
Description: LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly
Study: NCT04423224

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GDFM
Description: Stroke volume variation fluid management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: USUAL CARE - CONTROL
Description: Usual care fluid management
Study: NCT00472823

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate (Citracal)
Description: Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate (Citracal)
Description: Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate (Citracal)
Description: Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate (Citracal)
Description: Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate (Citracal)
Description: Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate (Citracal)
Description: Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate (Citracal)
Description: Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
Study: NCT02287363

Intervention type: OTHER
Intervention: No intervention involved
Description: No interventions will be involved since it is an observational study

Intervention type: OTHER
Intervention: No intervention involved
Description: No interventions will be involved since it is an observational study
Study: NCT04005781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
Study: NCT04733664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFI using the FAST PV Technology
Description: The bolus IV administered visible fluorescent injectate (VFI) agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
Study: NCT02067546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental toilet seat

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard toilet seat
Study: NCT03770728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide SAR439977
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide SAR439977
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide SAR439977
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy: Metformin alone or in combination with SU
Description: Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy: Metformin alone or in combination with SU
Description: Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy: Metformin alone or in combination with SU
Description: Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background therapy: Metformin alone or in combination with SU
Description: Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.